EVEROLIMUSBHT tailored to your needs
US NEWPORT CONSTRAINT DATE 2020
THERAPEUTIC INDICATION: ONCOLOGY
EVEROLIMUS is an oral prescription-strength medicine approved to treat certain types of cancer including advanced hormone receptor-positive, HER2-negative breast cancer, and advanced renal cell carcinoma. It is also indicated for the prophylaxis of organ rejection in kidney or liver transplantation.
- AFINITOR® as antineoplastic agent
- ZORTRESS® as immunosuppressant
- Our EVEROLIMUS can be tailored to your needs e.g. we can offer a customized BHT content of 2%, 1.2%, and 0%
- Few API sources active in the market
This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.